Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Johnson & Johnson
JNJ
Current price
$177.80
A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therap...
A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therapy.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
The FDA's approval of new bispecific antibodies for multiple myeloma has created a watershed moment for cancer treatment innovation. This validation opens doors for companies developing similar groundbreaking therapies that can command premium pricing while addressing critical patient needs.
What You Need to Know
This collection includes research-intensive biopharmaceutical companies focused on next-generation cancer treatments. These stocks represent a growth-oriented investment in biotechnology innovation, with companies ranging from established pharmaceutical giants to specialized biotech firms.
Why These Stocks
Each company was selected based on their direct involvement in developing advanced treatments for multiple myeloma. They're either pioneers who've received recent approvals, direct competitors with similar technologies, or key enablers of bispecific antibody and CAR-T therapies.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+136.34%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 136.34% over the next year.
Stocks Rated Buy by Analysts
11 of 15 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 3.3% return last month.
Why You'll Want to Watch These Stocks
Breakthrough Cancer Treatments
These companies are developing therapies that could transform survival rates for blood cancer patients. Recent FDA approvals validate both the technology and massive market potential.
Premium Pricing Power
Advanced cancer treatments command high prices due to their life-extending benefits. Companies with approved therapies for late-stage cancers can generate substantial revenue even with relatively small patient populations.
Scientific Innovation Leaders
This group includes pioneers in immunotherapy technologies that go beyond traditional treatments. Their innovations could potentially expand to other cancer types, multiplying their market opportunities.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.